# Janssen Pharmaceutica N.V., Belgium: Observational study closed enrollment, 1314 enrolled (Arthritis, Psoriatic)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Janssen Pharmaceutica N.V., Belgium |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice |
| NCT ID | NCT05049798 |
| Phase | Observational |
| Status | active not recruiting |
| Conditions | Arthritis, Psoriatic |
| Intervention types | drug |
| Target enrollment | 1314 |
| Site countries | Argentina, Australia, Austria, Belgium, Canada, Colombia, France, Germany, Greece, Italy, Japan, Mexico |
| Posted | 2021-09-20 |
| Planned start | 2021-08-25 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-03 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 1314 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05049798). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.